Gastrointestinal Stromal Tumors: All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).Proto-Oncogene Proteins c-kit: A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.Gastrointestinal Neoplasms: Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.Benzamides: BENZOIC ACID amides.PiperazinesPyrimidines: A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.Receptor, Platelet-Derived Growth Factor alpha: A PDGF receptor that binds specifically to both PDGF-A chains and PDGF-B chains. It contains a protein-tyrosine kinase activity that is involved in SIGNAL TRANSDUCTION.Stromal Cells: Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Mesenchymoma: A mixed mesenchymal tumor composed of two or more mesodermal cellular elements not commonly associated, not counting fibrous tissue as one of the elements. Mesenchymomas are widely distributed in the body and about 75% are malignant. (Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1866)Neoplasms, Connective Tissue: Neoplasms composed of connective tissue, including elastic, mucous, reticular, osseous, and cartilaginous tissue. The concept does not refer to neoplasms located in connective tissue.Epithelioid Cells: Characteristic cells of granulomatous hypersensitivity. They appear as large, flattened cells with increased endoplasmic reticulum. They are believed to be activated macrophages that have differentiated as a result of prolonged antigenic stimulation. Further differentiation or fusion of epithelioid cells is thought to produce multinucleated giant cells (GIANT CELLS).Mitotic Index: An expression of the number of mitoses found in a stated number of cells.Duodenal Neoplasms: Tumors or cancer of the DUODENUM.Pyrroles: Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.Leiomyosarcoma: A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Ileal Neoplasms: Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL).Jejunal Neoplasms: Tumors or cancer in the JEJUNUM region of the small intestine (INTESTINE, SMALL).Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Intestinal Neoplasms: Tumors or cancer of the INTESTINES.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Indoles: Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.Stomach Neoplasms: Tumors or cancer of the STOMACH.Protein Kinase Inhibitors: Agents that inhibit PROTEIN KINASES.Sex Cord-Gonadal Stromal Tumors: Neoplasms derived from the primitive sex cord or gonadal stromal cells of the embryonic GONADS. They are classified by their presumed histogenesis and differentiation. From the sex cord, there are SERTOLI CELL TUMOR and GRANULOSA CELL TUMOR; from the gonadal stroma, LEYDIG CELL TUMOR and THECOMA. These tumors may be identified in either the OVARY or the TESTIS.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Digestive System Surgical Procedures: Surgery performed on the digestive system or its parts.DNA Mutational Analysis: Biochemical identification of mutational changes in a nucleotide sequence.Neurofibromatosis 1: An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS).Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Carney Complex: Autosomal dominant syndrome characterized by cardiac and cutaneous MYXOMAS; LENTIGINOSIS (spotty pigmentation of the skin), and endocrinopathy and its associated endocrine tumors. The cardiac myxomas may lead to SUDDEN CARDIAC DEATH and other complications in Carney complex patients. The gene coding for the PRKAR1A protein is one of the causative genetic loci (type 1). A second locus is at chromosome 2p16 (type 2).Leiomyoma: A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.Gastrectomy: Excision of the whole (total gastrectomy) or part (subtotal gastrectomy, partial gastrectomy, gastric resection) of the stomach. (Dorland, 28th ed)Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Antigens, CD34: Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.Drug Resistance, Neoplasm: Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.Interstitial Cells of Cajal: c-Kit positive cells related to SMOOTH MUSCLE CELLS that are intercalated between the autonomic nerves and the effector smooth muscle cells of the GASTROINTESTINAL TRACT. Different phenotypic classes play roles as pacemakers, mediators of neural inputs, and mechanosensors.Endosonography: Ultrasonography of internal organs using an ultrasound transducer sometimes mounted on a fiberoptic endoscope. In endosonography the transducer converts electronic signals into acoustic pulses or continuous waves and acts also as a receiver to detect reflected pulses from within the organ. An audiovisual-electronic interface converts the detected or processed echo signals, which pass through the electronics of the instrument, into a form that the technologist can evaluate. The procedure should not be confused with ENDOSCOPY which employs a special instrument called an endoscope. The "endo-" of endosonography refers to the examination of tissue within hollow organs, with reference to the usual ultrasonography procedure which is performed externally or transcutaneously.Exons: The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Laparotomy: Incision into the side of the abdomen between the ribs and pelvis.Neurilemmoma: A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)Tumor Burden: The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.Somatostatinoma: A SOMATOSTATIN-secreting tumor derived from the pancreatic delta cells (SOMATOSTATIN-SECRETING CELLS). It is also found in the INTESTINE. Somatostatinomas are associated with DIABETES MELLITUS; CHOLELITHIASIS; STEATORRHEA; and HYPOCHLORHYDRIA. The majority of somatostatinomas have the potential for METASTASIS.Protein-Tyrosine Kinases: Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.Cell Line, Tumor: A cell line derived from cultured tumor cells.S100 Proteins: A family of highly acidic calcium-binding proteins found in large concentration in the brain and believed to be glial in origin. They are also found in other organs in the body. They have in common the EF-hand motif (EF HAND MOTIFS) found on a number of calcium binding proteins. The name of this family derives from the property of being soluble in a 100% saturated ammonium sulfate solution.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Leiomyoma, Epithelioid: A relatively rare smooth muscle tumor found most frequently in the wall of the gastrointestinal tract, especially in the stomach. It is similar to other smooth muscle tumors but may become very large and hemorrhage and exhibit small cystic areas. Simple excision is almost always curative. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1354)Gastroscopy: Endoscopic examination, therapy or surgery of the interior of the stomach.Electron Transport Complex II: A flavoprotein oxidase complex that contains iron-sulfur centers. It catalyzes the oxidation of SUCCINATE to fumarate and couples the reaction to the reduction of UBIQUINONE to ubiquinol.Positron-Emission Tomography: An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Peritoneal Neoplasms: Tumors or cancer of the PERITONEUM.Endoscopy, Gastrointestinal: Endoscopic examination, therapy or surgery of the gastrointestinal tract.Pelvic Neoplasms: Tumors or cancer of the pelvic region.Succinate Dehydrogenase: A flavoprotein containing oxidoreductase that catalyzes the dehydrogenation of SUCCINATE to fumarate. In most eukaryotic organisms this enzyme is a component of mitochondrial electron transport complex II.Double-Balloon Enteroscopy: Endoscopy of the small intestines accomplished while advancing the endoscope into the intestines from the stomach by alternating the inflation of two balloons, one on an innertube of the endoscope and the other on an overtube.Omentum: A double-layered fold of peritoneum that attaches the STOMACH to other organs in the ABDOMINAL CAVITY.Incidental Findings: Unanticipated information discovered in the course of testing or medical care. Used in discussions of information that may have social or psychological consequences, such as when it is learned that a child's biological father is someone other than the putative father, or that a person tested for one disease or disorder has, or is at risk for, something else.Ki-67 Antigen: A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Neurofibrosarcoma: A malignant tumor that arises from small cutaneous nerves, is locally aggressive, and has a potential for metastasis. Characteristic histopathologic features include proliferating atypical spindle cells with slender wavy and pointed nuclei, hypocellular areas, and areas featuring organized whorls of fibroblastic proliferation. The most common primary sites are the extremities, retroperitoneum, and trunk. These tumors tend to present in childhood, often in association with NEUROFIBROMATOSIS 1. (From DeVita et al., Cancer: Principles & Practice of Oncology, 5th ed, p1662; Mayo Clin Proc 1990 Feb;65(2):164-72)Gastrointestinal Hemorrhage: Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.Intestine, Small: The portion of the GASTROINTESTINAL TRACT between the PYLORUS of the STOMACH and the ILEOCECAL VALVE of the LARGE INTESTINE. It is divisible into three portions: the DUODENUM, the JEJUNUM, and the ILEUM.DNA, Neoplasm: DNA present in neoplastic tissue.Neoadjuvant Therapy: Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Hemoperitoneum: Accumulations of blood in the PERITONEAL CAVITY due to internal HEMORRHAGE.Biopsy, Needle: Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.Liver Neoplasms: Tumors or cancer of the LIVER.Lethargy: A general state of sluggishness, listless, or uninterested, with being tired, and having difficulty concentrating and doing simple tasks. It may be related to DEPRESSION or DRUG ADDICTION.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Meckel Diverticulum: A congenital abnormality characterized by the outpouching or sac formation in the ILEUM. It is a remnant of the embryonic YOLK SAC in which the VITELLINE DUCT failed to close.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Endometrial Stromal Tumors: Neoplasms of the endometrial stroma that sometimes involve the MYOMETRIUM. These tumors contain cells that may closely or remotely resemble the normal stromal cells. Endometrial stromal neoplasms are divided into three categories: (1) benign stromal nodules; (2) low-grade stromal sarcoma, or endolymphatic stromal myosis; and (3) malignant endometrial stromal sarcoma (SARCOMA, ENDOMETRIAL STROMAL).Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Kaplan-Meier Estimate: A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Gastrointestinal stromal tumors or (GISTs). GIST tumors are sarcomas derived from the GI tract's connective tissue whereas most ... A single mutation, D842V, in this exon accounts for >70% of GIST tumors. The next most common GIST tumor mutation occurs in ... GIST tumors occur throughout the GI track but most (66%) occur in the stomach and when developing there have a lower malignant ... potential than GIST tumors found elsewhere in the GI tract. The most common PDGFRA mutations found in GIST tumors occur in exon ...
Gastrointestinal stromal tumor (GIST). *Lymphoma. *Sarcoma. *Leiomyoma. *Metastatic tumors, especially SCLC or melanoma ... The small intestine or small bowel is an organ in the gastrointestinal tract where most of the end absorption of nutrients and ... See also: Gastrointestinal disease. The small intestine is a complex organ, and as such, there are a very large number of ... "The human gastrointestinal tract-specific transcriptome and proteome as defined by RNA sequencing and antibody-based profiling ...
Lasota J, Miettinen M (2007). "KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)". Semin Diagn Pathol. 23 (2 ... and gastrointestinal stromal tumors (GISTs). The efficacy of imatinib (trade name Gleevec), a CD117 inhibitor, is determined by ... gastrointestinal stromal tumors". Cancer Genet. Cytogenet. 135 (1): 1-22. doi:10.1016/S0165-4608(02)00546-0. PMID 12072198. ... Activating mutations in this gene are associated with gastrointestinal stromal tumors, testicular seminoma, mast cell disease, ...
... including SDH deficient Renal Carcinoma and SDH deficient Gastrointestinal Stromal Tumour (GIST). He founded and leads the ... "Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types". [1] "Cancer Diagnosis and ... is a standing member of the editorial board for the fifth edition of the World Health Organization classification of tumors. ... A Clinicopathologic Series of 36 Tumors From 27 Patients". " ...
2008). "Mutation assay of the novel gene DOG1 in gastrointestinal stromal tumors (GISTs)". J. Gastroenterol. 43 (7): 531-7. doi ... "Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including ... ANO1 is expressed in the human gastrointestinal epithelium and is highly expressed in the gastrointestinal interstitial cells ... 2009). "Ano1 is a selective marker of interstitial cells of Cajal in the human and mouse gastrointestinal tract". Am. J. ...
2010). "Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types". Am. J. Surg. ... SDHB is a tumor suppressor gene. Note the SDHA gene is not a tumor suppressor gene. Tumor formation generally follows the ... The penetrance of the gene is often reported as 77% by age 50 (i.e. 77% of carriers will have at least one tumour by the age of ... Tumor formation then becomes possible. Given the fundamental nature of the SDH protein in all cellular function, it is not ...
Gastrointestinal carcinoid tumor. *Gastrointestinal stromal tumor (GIST). *Hepatocellular cancer. *Pancreatic cancer, islet ... Not all tumors or lumps are cancerous; benign tumors are not classified as being cancer because they do not spread to other ... Benign tumors (which are not cancers) are usually named using -oma as a suffix with the organ name as the root. For example, a ... Germ cell tumor: Cancers derived from pluripotent cells, most often presenting in the testicle or the ovary (seminoma and ...
Gastrointestinal stromal tumors (GIST) are mesenchymal tumors that affect the gastrointestinal tract. Treatment options have ... is effective in the treatment of patients with metastatic gastrointestinal stromal tumors. Gastrointestinal stromal tumors ... Gastrointestinal stromal tumors (GIST) are known to withstand cancer chemotherapy treatment and do not respond to any kind of ... Therapy with imatinib can inhibit the non-normal cell signaling mechanisms in gastrointestinal stromal tumors. This results in ...
GISTs). However, there is limited evidence to suggest that the gastrointestinal stromal tumors (GIST) in Carney triad lack ... A third condition, the Carney-Stratakis syndrome (CSS), describes the dyad of hereditary gastrointestinal stromal tumor (GIST) ... Subsequent advances in molecular biology have led to the current terminology of gastrointestinal stromal tumors ( ... "Separate occurrence of extra-adrenal paraganglioma and gastrointestinal stromal tumor in monozygotic twins: probable familial ...
Roshanravan, Reza (2014). "Gastric Gastrointestinal Stromal Tumor (GIST) Incidentally Found After Laparoscopic Sleeve ... World Journal of Gastrointestinal Surgery. 7: 25. doi:10.4240/WJGS.v7.i3.25. Craanen, M. E. (1996). "Recent Developments in ... Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract. 17 (10): 1863-1868. ...
... is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other ... and certain types of gastrointestinal stromal tumors (GIST), systemic mastocytosis, and myelodysplastic syndrome. It is taken ... Some tumor cells, however, have a dependence on bcr-abl. Inhibition of the bcr-abl tyrosine kinase also stimulates its entry in ... The drug is also approved in unresectable KIT-positive GISTs. The FDA has approved imatinib for use in adults with relapsed or ...
Expression of RoXaN was found to be correlated with a higher tumor grad in GIST (gastrointestinal stromal tumors). GRCh38: ... "Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations". Proteomics. 6 (4): 1151-7 ...
Lasota J, Miettinen M (2007). „KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)". Semin Diagn Pathol. 23 (2 ... gastrointestinal stromal tumors". Cancer Genet. Cytogenet. 135 (1): 1-22. PMID 12072198. doi:10.1016/S0165-4608(02)00546-0.. ... Sandberg AA, Bridge JA (2002). „Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. ...
"Fear of progression in patients with gastrointestinal stromal tumors (GIST): Is extended lifetime related to the Sword of ...
... shown impressive results in treating chronic myelogenous leukemia and also promise in treating gastrointestinal stromal tumor ( ... GIST). Baltimore served as the Director of the Whitehead Institute until July 1, 1990 when he was appointed the sixth President ... Baltimore extended this work and examined two RNA tumor viruses, Rauscher murine leukemia virus and Rous sarcoma virus. He went ... The citation reads, "for their discoveries concerning the interaction between tumor viruses and the genetic material of the ...
Gastrointestinal stromal tumor (GIST) Hemangiopericytoma (9150)(Also known as "solitary fibrous tumor". Only a subset of these ... Some sarcomas, such as leiomyosarcoma, chondrosarcoma, and gastrointestinal stromal tumor (GIST), are more common in adults ... Desmoid Tumor (8821/1-8822/1) Desmoplastic small round cell tumor (8806/3) Epithelioid Sarcoma (8804/3) Extraskeletal ... Malignant peripheral nerve sheath tumor (MPNST) Neurofibrosarcoma (9540/3) Plexiform Fibrohistiocytic Tumor (8835/3) ...
During this time, he also studied gastrointestinal stromal tumors (GISTs), and worked with Dr. George Demetri to develop ... Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England Journal of Medicine. 347:472- ... "Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors". New England Journal of Medicine. 347: ... including the work that contributed to the idea that the stromal cells of pancreatic tumors act as a barrier for therapies. He ...
Lasota J, Miettinen M (2007). "KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)". Semin Diagn Pathol 23 (2 ... 2005). "PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib". J. Clin ...
... most notably Imatinib-mesylate in gastrointestinal stromal tumors (GISTs). Tyrosine kinase (a subclass of protein kinases) is ... Tumors more than 2 cm in diameter and tumors with necrosis and vascular invasion have been correlated with a worse outcome. The ... It targets tumor hypoxia, a common event in tumorigenesis where the tumor microenvironment is depleted of oxygen and becomes ... proximal location, smaller tumor size, and negative margins upon tumor resection. In general, epithelioid sarcoma is a slow- ...
... and gastrointestinal stromal tumors (GISTs). The fused BCR-Abl protein interacts with the interleukin-3 receptor beta(c) ... Although it did not eradicate CML cells, it did greatly limit the growth of the tumor clone and decreased the risk of the ...
It turns out that it targets other tyrosine kinase genes and can be used to control gastrointestinal stromal tumors (GISTs) ... July 2004). "A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor ... "A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors". Cancer Res ... The cancer stem-cell hypothesis relies on the fact that a lot of tumors are heterogeneous - the cells in the tumor vary by ...
... a marker indicating a gastrointestinal stromal tumor (GIST) will likely respond to imatinib treatment; and mutations in the ... Gonzalez RS, Carlson G, Page AJ, Cohen C (July 2011). "Gastrointestinal stromal tumor markers in cutaneous melanomas: ... Gastrointestinal stromal tumor), PSA (Prostate Specific Antigen) (Prostate Cancer), S100 (Melanoma), and many others. Mutant ... "Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients ...
... gastrointestinal stromal tumor (GIST), and glioma. Crenolanib is an orally bioavailable benzamidazole that selectively and ... "Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the ... of Gastrointestinal stromal tumor. Fusion of PDGFRA has been found to be responsible for hematological malignances like ... for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in ...
... unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and ... "FDA Approves Regorafenib (Stivarga) for GIST". CancerNetwork. 2013-02-26. Retrieved 2013-07-29. "Regorafenib Prescribing ... gastrointestinal and abdominal pain, rash, fever, and nausea. In 2011, Bayer entered into an agreement with Onyx under which ... is currently being studied as a potential treatment option in multiple tumor types. On 27 September 2012, the FDA approved ...
... for gastrointestinal stromal tumors (GIST) and mast cell tumors CD10 (CALLA): for renal cell carcinoma and acute lymphoblastic ... Most gastrointestinal stromal tumors express KIT, which can be detected by immunohistochemistry. Many proteins shown to be ... Gold JS, Dematteo RP (August 2006). "Combined Surgical and Molecular Therapy: The Gastrointestinal Stromal Tumor Model". Ann. ... Many tumors are hormone dependent. The presence of hormone receptors can be used to determine if a tumor is potentially ...
2011 that it was discontinuing a phase III trial of nilotinib as the first-line treatment of gastrointestinal stromal tumor ( ... GIST) based on the recommendation of an independent data monitoring committee. Interim results showed Tasigna is unlikely to ... Nilotinib has a number of adverse effects including headache, fatigue, gastrointestinal problems such as nausea, vomiting, ...
GIST) Help Forum. This forum is for help, questions and support regarding Gastrointestinal Stromal Tumor Community (GIST) ... Gastrointestinal Stromal Tumor Community (GIST) Community. WELCOME TO THE COMMUNITY: This Patient-To-Patient Community is for ... My husband has been battling GIST and last year had sugery to remove the tumor and was taking GLEEVEC to shrink the tumor.. an ... I had a gist tumor removed from my stomach 3 weeks ago. I had been progressing well, but last week, I began having a stabbing ...
Gastrointestinal stromal tumors (GISTs) are relatively rare neoplasms of the gastrointestinal tract originating from the ... The therapeutic approach to locally developed gastrointestinal stromal tumors is surgical resection, either with open or ... They are usually located in the upper gastrointestinal track. These tumors are typically defined by the expression of c-KIT ( ... CD117) and CD34 proteins in the tumor cells. A small percentage of these tumors is negative for c-KIT. The neoplasms are ...
GISTs) are a rare class of neoplasms that are seen most commonly in the stomach. Due to their malignant potential, surgical ... Laparoscopic resection of gastric gastrointestinal stromal tumors (GIST) is safe and effective, irrespective of tumor size. ... Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol 2008; 13: ... Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (GISTs): a size-matched comparison. Ann ...
This book provides a comprehensive and up-to-date overview of gastrointestinal stromal tumors (GISTs). ... ... This book provides a comprehensive and up-to-date overview of gastrointestinal stromal tumors (GISTs).. GISTs represent the ... Professionals involved in the management of GISTs inevitably cite significant evidence and the state-of-the-art treatments from ... Each expert author elucidates the cutting-edge knowledge on pathophysiology, diagnosis, and treatment of GISTs, especially ...
... gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents ... It is used for the treatment of metastatic colorectal cancer and advanced gastrointestinal stromal tumours. FDA approved on ...
Patients with gastrointestinal stromal tumors faced an increased risk for developing additional cancers before and after their ... Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumor of the GI tract, have always captured the ... Researchers used the SEER database to identify 6,112 patients diagnosed with gastrointestinal stromal tumor (GIST) between 2001 ... Patients with gastrointestinal stromal tumors faced an increased risk for developing additional cancers before and after their ...
keywords = "Angiogenesis inhibitor, Gastrointestinal stromal tumor (GIST), Motesanib",. author = "Akira Sawaki and Yasuhide ... Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib ... Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib ... Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib ...
Surprisingly, GIST-T1 was also highly sensitive to RITA despite lacking functional p53. This suggested a more complex, p53- ... To this end, we studied nutlin-3, an inhibitor of the p53 antagonist MDM2, and RITA, a putative p53 activator, in GIST cell ... The commonly used imatinib-sensitive cell lines GIST882 and GIST-T1 were shown to harbor defective p53 and therefore failed to ... Upregulation of p53 by MDM2 inhibitors has been shown to induce apoptosis in p53 wildtype tumors. Analyzing a series of 62 ...
... gastrointestinal stromal tumor - PharmQD. Bowtrol Probiotic improve gastrointestinal function & intestinal good bacterial ... Gastrointestinal- Stromal-Tumor-(GIST)) Gastrointestinal Stromal Tumor (GIST) GIST (gastrointestinal stromal tumor) is a ... story.rare-cancer.org/gastrointestinal-strom al-tumor.php) Gastrointestinal Stromal Tumor (GIST) GIST (gastrointestinal stromal ... Gastrointestinal- Stromal-Tumor-(GIST)) Gastrointestinal stromal tumor (GIST) is a type of tumor that usually begins in cells ...
Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most ... N2 - Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting ... AB - Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting ... abstract = "Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, ...
N2 - Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the gastrointestinal tract. ... AB - Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the gastrointestinal tract. ... Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the gastrointestinal tract. ... abstract = "Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the gastrointestinal ...
If the GIST is cancerous, your doctor will stage the tumor. This allows them to find the best treatment plan for you. Treatment ... As with many types of tumors, the symptoms of a GIST depend on its size, its location, and other factors. The most common ... About 4,000 to 60,000 people are diagnosed with this type of tumor each year in the United States. While GISTs are serious and ... GISTs) are a rare type of tumor that forms in the digestive system, typically in the stomach or small intestine. The exact ...
GISTs are typically defined by the expression of c-KIT (CD117) in the tumor cells, as these activating KIT mutations are see... ... GISTs) are mesenchymal neoplasms of the gastrointestinal (GI) tract and are thought to develop from the interstitial cells of ... encoded search term (Gastrointestinal Stromal Tumors (GISTs)) and Gastrointestinal Stromal Tumors (GISTs) What to Read Next on ... Gastrointestinal Stromal Tumors (GISTs) * Gastrointestinal Stromal Tumors (GISTs) Staging * Gastrointestinal Stromal Tumors ( ...
If you or someone you know has just been diagnosed with a gastrointestinal stromal tumor (GIST), this short, simple guide can ... If You Have a Gastrointestinal Stromal Tumor (GIST). What are GISTs?. Cancer can start any place in the body. A GIST ( ... If a GIST is found, tests can be done on the biopsy samples to help tell how quickly the tumor is likely to grow and spread. ... Not all GISTs need to be treated right away. Some small tumors that are likely to grow slowly can just be watched carefully. ...
Center has one of the largest and most experienced centers in New England for the treatment of gastrointestinal stromal tumor ... Gastrointestinal Stromal Tumor (GIST) Treatment Program. The Mass General Cancer Center has one of the largest and most ... Our multidisciplinary team of gastrointestinal stromal tumor cancer (GIST) specialists provides individualized care and ... tumors without using standard chemotherapy and radiation. GIST tumors often respond to oral anti-tumor drugs that have very few ...
Gastrointestinal Stromal Tumor (GIST) News and Research. RSS Gastrointestinal Stromal Tumor (GIST) is a type of tumor that ... Gastrointestinal Stromal Tumor (GIST) Treatment. *Gastrointestinal Stromal Tumor (GIST) Causes. *Gastrointestinal Stromal Tumor ... gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumor (PNET). ... positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the ...
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. MedHelp is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following ...
GIST) in this overview from Moffitt Cancer Center. ... the different surgery options for treating a gastrointestinal ... Surgery is typically the main form of treatment for a GIST, or a gastrointestinal stromal tumor. Surgical intervention can be ... Because gastrointestinal stromal tumors are prone to spreading if the lining that surrounds them is accidentally torn, surgical ... For large tumors, chemotherapy may be provided before a GIST surgery to shrink the tumor before it is removed. ...
Use the menu to see other pages.Doctors use many tests to find, or diagnose, a tumor. Your doctor may consider these factors ... when choosing a diagnostic test:The type of tumor suspectedYour signs and symptomsYour age and general health ... Gastrointestinal Stromal Tumor - GIST: Diagnosis. Gastrointestinal Stromal Tumor - GIST: Diagnosis. Approved by the Cancer.Net ... Gastrointestinal Stromal Tumor - GIST - Symptoms and Signs up Gastrointestinal Stromal Tumor - GIST - Stages › ...
You will find information about the number of people who are diagnosed with a GIST each year. You will also read general ... Gastrointestinal Stromal Tumor - GIST - Introduction up Gastrointestinal Stromal Tumor - GIST - Risk Factors › ... Gastrointestinal Stromal Tumor - GIST: Statistics. Approved by the Cancer.Net Editorial Board, 01/2019 ... GISTs are rare, making up less than 1% of all gastrointestinal tumors. Each year, approximately 4,000 to 6,000 adults in the ...
These tumors account for up to 3% of all gastrointestinal malignancies, with a reported annual incidence of 10-15 cases per ... The clinical presentation and tumor biology of GISTs are widely variable, with several advances being made over the past two ... GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract, occurring predominantly in the stomach and ... GISTs are thought to originate from interstitial cells of Cajal (ICC) or ICC precursor cells, and are characterized by ...
7.2 GIST Therapeutics: Implications for Future Market Competition 53. 8 Gastrointestinal Stromal Tumor (GIST) Therapeutics: ... 3 Gastrointestinal Stromal Tumor (GIST) Therapeutics: Market Characterization 12. 3.1 GIST Therapeutics Market Size (2005-2010 ... 6.5 Top Companies Participating in GIST Therapeutics Clinical Trials 51. 7 Gastrointestinal Stromal Tumor (GIST) Therapeutics: ... Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 ...
GISTs are very rare tumors that start in special cells in the wall of the GI tract that regulate your body processes, including ... What Are Gastrointestinal Stromal Tumors?. GISTs are very rare tumors that start in special cells in the wall of the GI tract, ... Gastrointestinal Stromal Tumors (GIST) Find a Doctor Request an Appointment Find a Clinical Trial ... GIST Second Opinions. We both give and welcome second opinions if you have been diagnosed with a gastrointestinal stromal tumor ...
GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST ... Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST). Official Title ICMJE A Phase II Randomized Multicentre Study ... Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) (PAZOGIST). This study has been completed. ... NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice ...
Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST). The safety and scientific validity of this ... Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST). Official Title ICMJE A Phase II Trial of TKI258 ... Gastrointestinal Stromal Tumors. Intervention ICMJE Drug: dovitinib TKI258 at 500 mg/day on a 5 days on/2 days off dosing ... in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib( ...
  • These NCCN Guideline Insights high-light the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib. (wustl.edu)
  • Each expert author elucidates the cutting-edge knowledge on pathophysiology, diagnosis, and treatment of GISTs, especially focusing on the highly valuable data from Japan. (frohberg.de)
  • Patients with gastrointestinal stromal tumors faced an increased risk for developing additional cancers before and after their diagnosis, according to results of a SEER analysis. (healio.com)
  • Researchers calculated standardized prevalence ratios (SPR) - or cancer occurrence before GIST diagnosis - and standardized incidence ratios, or the risk for cancer after GIST diagnosis, by comparing data from the patients with data from the general U.S. population in 2000. (healio.com)
  • Malignancies with significantly increased occurrence rates only prior to a GIST diagnosis included esophageal adenocarcinoma (SPR = 12), bladder adenocarcinoma (SPR = 7.51), melanoma (SPR = 1.46) and prostate adenocarcinoma (SPR =1.2). (healio.com)
  • Occurrence rates were significantly increased only after a GIST diagnosis for ovarian carcinoma (SIR = 8.72), small intestine adenocarcinoma (SIR = 5.89), papillary thyroid cancer (SIR = 5.16), renal cell carcinoma (SIR = 4.46), hepatobiliary adenocarcinoma (SIR = 3.1), gastric adenocarcinoma (SIR = 2.7), pancreatic adenocarcinoma (SIR = 2.03), uterine adenocarcinoma (SIR = 1.96), non-small cell lung cancer (SIR =1.74) and transitional cell carcinoma of the bladder (SIR =1.65). (healio.com)
  • Researchers observed a higher incidence of additional cancers before a GIST diagnosis among non-Hispanic white patients compared with Hispanic patients ( P = .02). (healio.com)
  • In this study, we tried to identify predictors of recurrence in resectable GISTs. (ncku.edu.tw)
  • Multivariate analysis demonstrated that tumor size ≥10 cm was associated with higher recurrence rates (P = .032) and was the only independent poor prognostic factor for survival (P = .020). (ncku.edu.tw)
  • Conclusions: We concluded that tumor size ≥10 cm carried both a higher risk of recurrence and worse survival in resectable GISTs and could be considered an indicator for adjuvant therapy. (ncku.edu.tw)
  • The researchers acknowledged these data may be limited by a detection bias during the evaluation for symptomatic patients or follow-up after GIST treatment, which may lead to elevated occurrences of additional cancers. (healio.com)
  • Efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumor, and safety was assessed according to the Common Terminology Criteria for Adverse Events (version 3). (elsevier.com)
more